Autolus Therapeutics plc Q1 FY2026 earnings call

Commercial Launch Performance

• OCATSL has strong commercial traction in the U.S., with 73 active centers as of Q1 2026, on track to reach over 80 centers by the end of 2026.
• The UK launch is off to a strong start, with over 10 active centers already onboarding patients through the NHS access program. Centralized NHS decision-making is accelerating onboarding, potentially faster than the initial U.S. rollout.
• Real-world data from the ROCA consortium, representing ~60% of commercial patients, confirms a positive safety profile (no high-grade CRS, only 3% high-grade ICANS) and a 90%+ overall response rate, including positive outcomes in older, comorbid, and lower tumor burden patients expanding the eligible patient pool.

Operational Efficiency and Restructuring

• After establishing a foundation of consistent high-quality product supply, management shifted to operational optimization and cost reduction, including a 13% company-wide reduction in force.
• These changes enabled the first positive gross margin in Q1 2026, driven by higher sales volume and improved manufacturing efficiency; the company expects to produce twice as much product in 2026 as 2025 with staffing at or below 2025 levels.
• After one-time restructuring costs, the company expects annualized net cost savings of $15 million starting in 2027. Peak gross margin for the ALL business is projected to reach 65-70%.

Pipeline Development Progress

• The phase 2 catalyst study expanding OCATSL to pediatric ALL is ongoing, with FDA-aligned protocol design for potential registration, and data expected at the end of 2027.
• The Carlisle study for OCATSL in refractory systemic lupus erythematosus (SLE) is progressing, with additional follow-up data expected by the end of 2026.
• The LUMINA registrational phase 2 study for refractory lupus nephritis is actively enrolling across the U.S. and Europe, with data expected in 2028. The trial targets an underserved refractory population and only requires 30 patients, so management does not expect enrollment delays despite competing studies.
• The Bobcat phase 1 study for progressive multiple sclerosis (MS) is enrolling, with initial safety and pharmacodynamic data expected by the end of 2026 and full clinical data in 2027.
• The Alaric phase 1 study for light chain amyloidosis, in collaboration with UCL, is on track to deliver initial data by the end of 2026. Additional real-world data continues to be collected through the ROCA consortium, and investigator-sponsored trials are exploring OCATSL in frontline consolidation settings.

Out of Loss Therapeutics has one core commercial product segment, OCATSL (Ocapsyl) for acute lymphoblastic leukemia (ALL). In Q1 2026, total net product revenue for OCATSL was $26.2 million, compared to $9 million in Q1 2025. The UK launch contribution was minimal in the quarter, with all revenue driven primarily by U.S. sales. OCATSL achieved its first positive gross margin of $1.6 million in Q1 2026, compared to gross losses in all prior 2025 quarters. Cost of sales for the quarter totaled $24.6 million, up from $18 million in Q1 2025, reflecting higher sales volume. Research and development (R&D) expenses across all pipeline segments were $21.2 million in Q1 2026, down from $26.7 million in Q1 2025, due to lower clinical trial and manufacturing supply costs for prior programs. Selling, general, and administrative (SG&A) expenses were $39.9 million, up from $29.5 million in Q1 2025, driven by commercialization costs for the U.S. and UK launches and one-time restructuring termination expenses. Operating loss was $59.5 million in Q1 2026, down from $65.2 million in Q1 2025, and net loss was $71.6 million compared to $70.2 million in the prior year quarter.

• Full year 2026 net product revenue guidance for OCATSL is maintained at $120 to $135 million, including expected contributions from both the U.S. and UK markets. Management noted positive market trends but is keeping guidance unchanged at this early point in the year, with plans to update if the sales trajectory changes. • The ALL business is projected to reach profitability in 2028. Company-level profitability by late 2027 will depend on the level of reinvestment in pipeline and commercial expansion over the next 18 months. • Gross margin is expected to improve steadily throughout 2026, driven by volume increases and implemented operational efficiency changes; management did not provide a specific full-year 2026 gross margin target. Most of the major productivity gains needed to approach peak 65-70% gross margin are expected to be realized during 2026. • As of March 31, 2026, cash, cash equivalents, and marketable securities totaled $229.4 million, which management expects to be sufficient to fund operations into Q4 2027.

• Forward-looking statements around clinical trial timelines, regulatory approval, commercial launch, and revenue are subject to risks and uncertainties that could cause actual results to differ materially from expectations, as detailed in the company's SEC filings and public disclosures. • European market access negotiations are ongoing and face uncertainty related to ongoing regional policy changes, and the company has not provided guidance for European sales at this stage.

• Clinical trial readouts for early-stage programs, particularly the progressive MS Bobcat study, require longer observation periods to generate stable, meaningful clinical efficacy data, which could lead to misinterpretation of early year-end 2026 data.
• The company relies on in-house manufacturing capacity, and scaling production for large potential indications like progressive MS may require new manufacturing partnerships, such as the ongoing feasibility study with Solaris, which carries technical and timing risk.

Q: Market expansion into older and harder-to-treat patients has been positive, but guidance was unchanged. Why maintain current full-year guidance? / A: Management notes the positive market dynamic is early in the year, so the current $120-$135 million revenue range remains reasonable. The company will continue monitoring trends and update the market if the sales trajectory shifts significantly from current projections.

Q: How is UK rollout cadence progressing compared to the U.S., and how will R&D spend evolve for the full year? / A: UK onboarding is proceeding at least as fast as the initial U.S. rollout, and may be faster, due to centralized NHS decision-making that accelerates patient access approvals. For R&D spend, quarterly fluctuations come from transitioning between trial phases and winding down older program costs, such as Felix study follow-up and manufacturing capacity mobilization. These cost reductions offset rising enrollment and supply costs for new trials, so management expects full-year R&D spend to remain at a fairly steady level, with no major new infrastructure additions planned.

Q: When do you expect to reach peak 65-70% gross margin, and what is your commercialization plan for progressive MS? / A: Peak sales penetration for the ALL indication is expected to take 4-5 years from launch, but most of the gross margin improvement will occur earlier, with the largest productivity and fixed cost allocation gains realized during 2026. For MS, the patient population is far larger and more geographically distributed than ALL, so management is actively exploring a commercial partnership to support launch, given the scale of the opportunity.

Q: What is driving OCATSL's Q1 growth: new center expansion or greater utilization at existing centers, and what market coverage will 80 centers provide? / A: The majority of Q1 growth came from increased utilization at the 73 already active centers, rather than new center adds. Management tracks growing physician adoption within active centers as a key metric, and sees consistent progression in the number of physicians per center that have dosed patients. 80 centers by end of 2026 will cover approximately 80% of the eligible U.S. patient population, with continued growth coming from broader physician adoption within those covered centers.